A macaque model of HIV-1 infection

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 11, 2009, Pages 4425-4429

  Hatziioannou, Theodora ^a   Ambrose, Zandrea ^b,e   Chung, Nancy P Y ^b   Piatak Jr , Michael ^c   Yuan, Fang ^c   Trubey, Charles M ^c   Coalter, Vicky ^c   Kiser, Rebecca ^c   Schneider, Doug ^c   Smedley, Jeremy ^c   Pung, Rhonda ^c   Gathuka, Mercy ^c   Estes, Jacob D ^c   Veazey, Ronald S ^d   Kewalramani, Vineet N ^b   Lifson, Jeffrey D ^c   Bieniasz, Paul D ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

^d TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; PrEP; SIV; StHIV 1

Indexed keywords

AMPRENAVIR; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; ATAZANAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; TENOFOVIR DISOPROXIL; TRIPARTITE MOTIF PROTEIN 5; VIF PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE MODEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MACACA; MONKEY DISEASE; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTI-HIV AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CHEMOPREVENTION; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HIV INFECTIONS; HIV-1; MACACA; VIREMIA; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA NEMESTRINA; PRIMATES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 63149135737     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0812587106     Document Type: Article

References (47)

1. Ambrose Z, Kewal Ramani VN, Bieniasz PD, Hatziioannou T (2007) HIV/AIDS: in search of an animal model. Trends Biotechnol 25:333-337.
2. Fultz PN (1993) Nonhuman primate models for AIDS. Clin Infect Dis 17 Suppl 1:S230-S235.
3. Daniel MD, et al. (1985) Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 228:1201-1204.
4. Reimann KA, et al. (1996) A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 70:6922-6928.
5. Harouse JM, Gettie A, Tan RC, Blanchard J, Cheng-Mayer C (1999) Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284:816-819.
6. Uberla K, et al. (1995) Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci USA 92:8210-8214.
7. Ambrose Z, et al. (2007) Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol 81:12145-12155.
8. Lackner AA, Veazey RS (2007) Current concepts in AIDS pathogenesis: insights from the SIV/macaque model. Annu Rev Med 58:461-476.
9. Nishimura Y, et al. (2004) Highly pathogenic SHIVs and SIVs target different CD4+T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc Natl Acad Sci USA 101:12324-12329.
10. Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J (1999) Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med 5:535-541.
11. Stremlau M, et al. (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848-853.
12. Stremlau M, et al. (2006) Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci USA 103:5514-5519.
13. Sebastian S, Luban J (2005) TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2:40.
14. Perez-Caballero D, Hatziioannou T, Yang A, Cowan S, Bieniasz PD (2005) Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol 79:8969-8978.
15. Yap MW, Nisole S, Stoye JP (2005) A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 15:73-78.
16. Sawyer SL, Wu LI, Emerman M, Malik HS (2005) Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci USA 102:2832-2837.
17. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
18. Harris RS, et al. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809.
19. Mangeat B, et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103.
20. Zhang H, et al. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98.
21. 21.Yu X, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060.
22. Marin M, Rose KM, Kozak SL, Kabat D (2003) HIV-1 Vif protein bindsthe editing enzyme APOBEC3G and induces its degradation. Nat Med 9:1398-1403.
23. Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9:1404-1407.
24. Mariani R, et al. (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31.
25. Xu H, et al. (2004) A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci USA 101:5652-5657.
26. Mangeat B, Turelli P, Liao S, Trono D (2004) A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem 279:14481-14483.
27. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR (2004) A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci USA 101:3770-3774.
28. Virgen CA, Hatziioannou T (2007) Antiretroviral activity and Vif sensitivity of rhesus macaque APOBEC3 proteins. J Virol 81:13932-13937.
29. Shibata R, Sakai H, Kawamura M, Tokunaga K, Adachi A (1995) Early replication block of human immunodeficiency virus type 1 in monkey cells. J Gen Virol 76 (Pt 11):2723-2730.
30. Hatziioannou T, et al. (2006) Generation of simian-tropic HIV-1 by restriction factor evasion. Science 314:95.
31. Kamada K, et al. (2006) Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. Proc Natl Acad Sci USA 103:16959-16964.
32. Virgen CA, Kratovac Z, Bieniasz PD, Hatziioannou T (2008) Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proc Natl Acad Sci USA 105:3563-3568.
33. Newman RM, et al. (2008) Evolution of a TRIM5-CypA splice isoform in old world monkeys. PLoS Pathog 4:e1000003.
34. Wilson SJ, et al. (2008) Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc Natl Acad Sci USA 105:3557-3562.
35. Brennan G, KozyrevY, Hu SL (2008) TRIMCyp expression in Old World primates Macaca nemestrina and Macaca fascicularis. Proc Natl Acad Sci USA 105:3569-3574.
36. Liao CH, Kuang YQ, Liu HL, Zheng YT, Su B (2007) A novel fusion gene, TRIM5-Cyclophilin A in the pig-tailed macaque determines its susceptibility to HIV-1 infection. Aids 21 Suppl 8:S19-S26.
37. Sayah DM, Sokolskaja E, Berthoux L, Luban J (2004) Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430:569-573.
38. Nisole S, Lynch C, Stoye JP, Yap MW (2004) A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc Natl Acad Sci USA 101:13324-13328.
39. Schmitz JE, et al. (1999) A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody. Am J Pathol 154:1923-1932.
40. Desrosiers RC (2004) Prospects for an AIDS vaccine. Nat Med 10:221-223.
41. Grant RM, et al. (2005) AIDS Promote HIV chemoprophylaxis research, don't prevent it. Science 309:2170-2171.
42. Tsai CC, et al. (1995) Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 270:1197-1199.
43. Agy MB, et al. (1992) Infection of Macaca nemestrina by human immunodeficiency virus type-1. Science 257:103-106.
44. Gartner S, et al. (1994) HIV-1 infection in pigtailed macaques. AIDS Res Hum Retroviruses 10 Suppl 2:S129-S133.
45. Kent SJ, et al. (1995) Cytotoxic and proliferative T cell responses in HIV-1-infected Macaca nemestrina. J Clin Invest 95:248-256.
46. Igarashi T, et al. (2007) Human immunodeficiency virus type 1 derivative with 7% simian immunodeficiency virus genetic content is able to establish infections in pig- tailed macaques. J Virol 81:11549-11552.
47. Sato S, Johnson W (2007) Antibody-mediated neutralization and simian immunodeficiency virus models of HIV/AIDS. Curr HIV Res 5:594-607.